TRPV4
ENSG00000111199
Target class
Ion channel
Chromosome
12
Approved drugs
2
Clinical candidates (approved and in development)
3
- Approved drugs
- 2
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 3
- Chemical probe available
- Yes
- Target name
- TRPV4
- Gene name
- Transient receptor potential cation channel subfamily V member 4
- Gene symbol
- TRPV4
- Protein name
- Transient receptor potential cation channel subfamily V member 4 (TrpV4) (Osm-9-like TRP channel 4) (OTRPC4) (Transient receptor potential protein 12) (TRP12) (Vanilloid receptor-like channel 2) (Vanilloid receptor-like protein 2) (VRL-2) (Vanilloid receptor-related osmotically-activated channel) (VR-OAC)
- OTRPC4
- TRP12
- VROAC
- VRL-2
- VR-OAC
- CMT2C
- Gene biotype
- Protein coding
- Gene family
- Transient receptor potential cation channels|Ankyrin repeat domain containing
- Target class
- Ion channel
- Target type
- Human gene
- Tissues expressed in
- 25
- Highest tissue expression
- 28.02
- Tissue specificity (Gini)
- 0.704
- Tissue specificity (tau)
- 0.914
- KEGG gene identifiers
- hsa:59341
- Protein interaction confidence
- 0.836929
- Protein interaction partners
- 42
- R-HSA-3295583
- R-HSA-9856530
- End position
- 109833406
- Start position
- 109783087
- Chromosome
- 12
- Strand
- Reverse
- Cell membrane . Apical cell membrane
- Multi-pass membrane protein . Cell junction, adherens junction . Cell projection, cilium . Note=Assembly of the putative homotetramer occurs primarily in the endoplasmic reticulum (PubMed:16293632, PubMed:20037587, PubMed:20037588). Localization to the cell membrane is inhibited by WNK kinases (WNK1, WNK2, WNK3 or WNK4) in a kinase-independent mechanism (PubMed:16403833). .
- SUBCELLULAR LOCATION: [Isoform 1]: Cell membrane .
- SUBCELLULAR LOCATION: [Isoform 5]: Cell membrane .
- SUBCELLULAR LOCATION: [Isoform 2]: Endoplasmic reticulum .
- SUBCELLULAR LOCATION: [Isoform 4]: Endoplasmic reticulum .
- SUBCELLULAR LOCATION: [Isoform 6]: Endoplasmic reticulum .
- PubMed 16403833
- PubMed 29899501
- PubMed 18695040
- PubMed 18826956
- PubMed 16293632
- PubMed 20037587
- PubMed 20037588
- PubMed 21964574
- PubMed 25256292
- Tissue specificity (tau)
- 0.914219
- Expression inequality (Gini)
- 0.703927
Expression in transcripts per million
- Minor Salivary Gland
- 28.02
- Esophagus - Mucosa
- 13.39
- Kidney - Cortex
- 13.34
- Prostate
- 12.79
- Skin - Sun Exposed (Lower leg)
- 11.96
Expression in transcripts per million
- Minor Salivary Gland28.02
- Esophagus - Mucosa13.39
- Kidney - Cortex13.34
- Prostate12.79
- Skin - Sun Exposed (Lower leg)11.96
- Skin - Not Sun Exposed (Suprapubic)11.19
- Kidney - Medulla11.14
- Liver4.76
- Spleen4.5
- Pituitary4.08
- Vagina3.61
- Lung3.08
- Pancreas2.76
- Cells - Cultured fibroblasts2.69
- Breast - Mammary Tissue2.27
- Thyroid2.05
- Testis1.91
- Artery - Aorta1.84
- Bladder1.6
- Artery - Coronary1.6
- Nerve - Tibial1.55
- Adipose - Visceral (Omentum)1.42
- Cervix - Endocervix1.27
- Adipose - Subcutaneous1.12
- Adrenal Gland1.1
And 29 more, listed on the interactive page.
- GO:0006816
- GO:0006874
- GO:0006884
- GO:0007204
- GO:0007231
- GO:0009612
- GO:0043117
- GO:0050891
- GO:0060351
- GO:0070588
- GO:0071476
- GO:0097497
- GO:1902656
- GO:0005783
- GO:0005886
- GO:0016324
- GO:0005261
- GO:0005262
- GO:0005515
- GO:0005516
- GO:0015275
- GO:0019901
- GO:0042802
Related records
Trials (2,786)
- "Curcumin" in Combination With Chemotherapy in Advanced Breast Cancer
- "Volatile Anesthetic Protection Of Renal Transplants: VAPOR-1-trail
- 12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder
- 18-Month Study of Memory Effects of Curcumin
- 4-methylpyrazole and Acetaminophen Metabolism
- A "Window Trial" on Curcumin for Invasive Breast Cancer Primary Tumors
- A 12-Week Efficacy Study of Paracetamol 1000mg Sustained-release Tablets in Patients With Osteoarthritis
- A 2×2 Factorial Randomized Controlled Trial for ERCP
- A 56-Week Extension to a Clinical Study to Assess the Efficacy and Safety of Vildagliptin Compared to Placebo in Drug Naive Patients With Type 2 Diabetes and Mild Hyperglycemia
- A Bioequivalence Study Between Two Brands of Medications to Treat Cough & Cold Symptoms
- A Bioequivalence Study of a New Paracetamol Oral Suspension 24mg/ml Compared to the Marketed Paracetamol Oral Suspension (Panadol Baby and Infant 24mg/ml) in Healthy Adult Subjects
- A Clinical Study Evaluating Sedation of Intravenous Administration of HSK3486 in ICU Patients Undergoing Long-Term Mechanical Ventilation
- A Clinical Study of Remimazolam Tosilate Compared to Propofol for General Anesthesia During Elective Surgery
- A Clinical Study of Remimazolam Tosilate in Patients Undergoing Bronchoscopy
- A Clinical Study to Assess the Effect of Vildagliptin on Beta Cell Function in Drug Naive Patients With Type 2 Diabetes
- A Clinical Study to Assess the Effect of Vildagliptin on Postprandial Lipid Parameters in Patients With Type 2 Diabetes
- A Clinical Study to Assess the Efficacy and Safety of Three Doses of Vildagliptin in Patients With Type 2 Diabetes
- A Clinical Study to Assess the Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes
- A Clinical Trial Evaluating the Efficacy and Safety of HSK3486 Injectable Emulsion in Elective Surgery Patients
- A Clinical Trial of GRT7040 in Adults With Acute Pain Following Bunionectomy
Drugs (9)
- Acetaminophen
- Butamben Transient receptor potential cation channel subfamily V member 4 inhibitor
- Butamben picrate Transient receptor potential cation channel subfamily V member 4 inhibitor
- Curcumin
- GSK2798745 Transient receptor potential cation channel subfamily V member 4 antagonist
- Phorbol myristate acetate
- Propofol
- Puerarin
- Vildagliptin